Tumor necrosis factor α Induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts

Arthritis and Rheumatism

Volumn 65, Issue 4, 2013, Pages 928-938

  Lee, Angela ^a   Qiao, Yu ^a   Grigoriev, Galina ^a   Chen, Janice ^a   Park Min, Kyung Hyun ^a   Park, Sung Ho ^a   Ivashkiv, Lionel B ^a   Kalliolias, George D ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A20 BINDING INHIBITOR OF NUCLEAR FACTOR KAPPA B ACTIVATION 3; ACTIVATING TRANSCRIPTION FACTOR 3; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MESSENGER RNA; RANTES; RNA POLYMERASE II; STROMELYSIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEEDBACK SYSTEM; FIBROBLAST; FIBROBLAST LIKE SYNOVIOCYTE; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; INFLAMMATION; MACROPHAGE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; OSTEOARTHRITIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875721405     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37853     Document Type: Article

References (50)

1. McInnes IB, Schett G,. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
2. Dadoun S, Zeboulon-Ktorza N, Combescure C, Elhai M, Rozenberg S, Gossec L, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2012. E-pub ahead of print.
3. Firestein GS,. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
4. Klareskog L, Malmstrom V, Lundberg K, Padyukov L, Alfredsson L,. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 2011; 23: 92-8.
5. Feldmann M,. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 2009; 27: 1-27.
6. Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 2012; 14: R68.
7. Fox DA,. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives [review]. Arthritis Rheum 1997; 40: 598-609.
8. Murakami M, Okuyama Y, Ogura H, Asano S, Arima Y, Tsuruoka M, et al. Local microbleeding facilitates IL-6- and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med 2011; 208: 103-14.
9. Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 2002; 3: 360-5.
10. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages [published erratum appears in Nature 2007;446:102]. Nature 2006; 443: 998-1002.
11. Kawane K, Tanaka H, Kitahara Y, Shimaoka S, Nagata S,. Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci U S A 2010; 107: 19432-7.
12. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G,. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387-98.
13. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G,. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008; 205: 331-7.
14. Bartok B, Firestein GS,. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-55.
15. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996; 149: 1607-15.
16. Noss EH, Brenner MB,. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev 2008; 223: 252-70.
17. Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M,. Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest 1989; 83: 585-92.
18. Firestein GS, Zvaifler NJ,. How important are T cells in chronic rheumatoid synovitis? [editorial]. Arthritis Rheum 1990; 33: 768-73.
19. Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM, et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 3866-77.
20. Cho CS, Cho ML, Min SY, Kim WU, Min DJ, Lee SS, et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol 2000; 164: 5055-61.
21. Buckley CD,. Why does chronic inflammation persist: an unexpected role for fibroblasts. Immunol Lett 2011; 138: 12-4.
22. Ivashkiv LB,. Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation states. Eur J Immunol 2011; 41: 2477-81.
23. Park SH, Park-Min KH, Chen J, Hu X, Ivashkiv LB,. Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat Immunol 2011; 12: 607-15.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
25. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 1039-49.
26. Parsonage G, Falciani F, Burman A, Filer A, Ross E, Bofill M, et al. Global gene expression profiles in fibroblasts from synovial, skin and lymphoid tissue reveals distinct cytokine and chemokine expression patterns. Thromb Haemost 2003; 90: 688-97.
27. Gordon RA, Grigoriev G, Lee A, Kalliolias GD, Ivashkiv LB,. The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment. Arthritis Rheum 2012; 64: 3119-28.
28. Muller-Ladner U, Gay RE, Gay S,. Role of nuclear factor κB in synovial inflammation. Curr Rheumatol Rep 2002; 4: 201-7.
29. Ghosh G, Wang VY, Huang DB, Fusco A,. NF-κB regulation: lessons from structures. Immunol Rev 2012; 246: 36-58.
30. Chen J, Ivashkiv LB,. IFN-γ abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc Natl Acad Sci U S A 2010; 107: 19438-43.
31. Foster SL, Hargreaves DC, Medzhitov R,. Gene-specific control of inflammation by TLR-induced chromatin modifications [published erratum appears in Nature 2008;451:102]. Nature 2007; 447: 972-8.
32. Mosser DM, Edwards JP,. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-69.
33. Lang R,. Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiology 2005; 210: 63-76.
34. Williams LM, Sarma U, Willets K, Smallie T, Brennan F, Foxwell BM,. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J Biol Chem 2007; 282: 6965-75.
35. Rosengren S, Corr M, Firestein GS, Boyle DL,. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; 71: 440-7.
36. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108: 73-81.
37. Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, et al. PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol 2012; 180: 1906-16.
38. Devauchelle V, Essabbani A, De Pinieux G, Germain S, Tourneur L, Mistou S, et al. Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J Immunol 2006; 177: 6471-9.
39. Yamana J, Morand EF, Manabu T, Sunahori K, Takasugi K, Makino H, et al. Inhibition of TNF-induced IL-6 by the TWEAK-Fn14 interaction in rheumatoid arthritis fibroblast like synoviocytes. Cell Immunol 2012; 272: 293-8.
40. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 2012; 209: 925-33.
41. Orosa B, Gonzalez A, Mera A, Gomez-Reino JJ, Conde C,. Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to tumor necrosis factor-induced apoptosis. Arthritis Rheum 2012; 64: 2460-70.
42. Fu D, Yang Y, Xiao Y, Lin H, Ye Y, Zhan Z, et al. Role of p21-activated kinase 1 in regulating the migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. Rheumatology (Oxford) 2012; 51: 1170-80.
43. Nishimoto N, Kishimoto T,. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619-26.
44. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
45. Jones SA, Scheller J, Rose-John S,. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-83.
46. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al, for the ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
47. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al, for the ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
48. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug- induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-73.
49. Walsh NC, Gravallese EM,. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010; 233: 301-12.
50. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315: 1006-10.